Great Overview Article on $BSTG Biostage Inc. in W
Post# of 4
Holliston Biotech Seeks to fulfill $1.5-billion potential
Discusses current research and plans to file and IND with the FDA to initiate human clinical trials of its Cellspan esophageal organ implant.
Biostage, Inc. (BSTG) Stock Research Links
David Collins, Managing Director
Catalyst Global Investor Relations
www.catalyst-ir.com
dcc@catatalyst-ir.com
212 924 9800